EC approves Obgemsa for overactive bladder

French privately-held drugmaker Pierre Fabre revealed that the European Commission (EC) has authorized the marketing of its Obgemsa (vibegron) for the symptomatic treatment of overactive bladder syndrome in adults, a particularly debilitating condition affecting over 70 million patients in Europe.

In 2022, Pierre Fabre Laboratories acquired the exclusive license for vibegronfrom Urovant Sciences for the registration and commercialization of this innovative treatment in the European Economic Area. The decision of the EC will be applicable to all European Union (EU) member states as well as Iceland, Liechtenstein, and Norway. Obgemsa is a trademark owned by Urovant Sciences.

Pierre Fabre chief executive Eric Ducournau commented: "We are delighted with this development, which will allow European patients to benefit from a new therapeutic option for overactive bladder syndrome and further strengthen our expertise of over 40 years in urology. This decision confirms Pierre Fabre Laboratories' commitment to offering patients innovative therapies that provide better management of chronic debilitating diseases."